View Older Stories
-
GeneDx posts 41% revenue growth, issues 2026 guidance
-
GeneDx partners with Komodo Health to create rare disease dataset
-
GeneDx launches prenatal whole genome sequencing test
-
BTIG: 'we name GH and WGS as 2026 Top Picks'
-
GeneDx Holdings (WGS) Tops Q3 EPS by 8c; Offers Guidance
-
GeneDx (WGS) PT Raised to $170 at Guggenheim
-
GeneDx (WGS) PT Raised to $165 at BTIG
-
GeneDx Holdings (WGS) files mixed shelf
-
GeneDx receives FDA breakthrough device designation for genome tests
-
Canaccord Genuity Starts GeneDx (WGS) at Buy
-
Illumina constellation technology identifies hard-to-detect genetic variants
-
GeneDx names Dr. Mimi Lee as chief precision medicine officer
-
GeneDx joins $14.4 million NIH-funded genomic newborn screening study
-
GeneDx names Lisa Gurry as chief business officer
-
GeneDx (WGS) PT Raised at Piper Sandler; 'We Recommend Buying More on a Pullback'
-
Piper Sandler on GeneDx (WGS): 'Visibility to a Multiyear Growth Cycle'
-
GeneDx (WGS) PT Raised to $125 at BTIG
-
GeneDx Holdings (WGS) Tops Q2 EPS by 38c ; Offers Guidance
-
ROSEN, A LEADING LAW FIRM, Encourages GeneDx Holdings Corp. Investors to Inquire About Securities Class Action Investigation - WGS
-
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages GeneDx Holdings Corp. Investors to Inquire About Securities Class Action Investigation - WGS
-
Piper Sandler Starts GeneDx (WGS) at Overweight
-
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages GeneDx Holdings Corp. Investors to Inquire About Securities Class Action Investigation - WGS
-
ROSEN, SKILLED INVESTOR COUNSEL, Encourages GeneDx Holdings Corp. Investors to Inquire About Securities Class Action Investigation - WGS
-
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages GeneDx Holdings Corp. Investors to Inquire About Securities Class Action Investigation - WGS
-
ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages GeneDx Holdings Corp. Investors to Inquire About Securities Class Action Investigation - WGS
-
GeneDx (WGS) PT Raised to $105 at Jefferies
-
GeneDx (WGS) announces AAP now recommends exome and genome sequencing
-
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages GeneDx Holdings Corp. Investors to Inquire About Securities Class Action Investigation - WGS
-
ROSEN, A LEADING NATIONAL FIRM, Encourages GeneDx Holdings Corp. Investors to Inquire About Securities Class Action Investigation - WGS
-
GeneDx Holdings (WGS) spreader July 70 and 80 calls as share price down 5.7%
-
Jefferies Upgrades GeneDx (WGS) to Buy
-
GeneDx Holdings (WGS) call put ratio 1 call to 1.3 puts as share price down
-
GeneDx (WGS) PT Lowered to $100 at BTIG
-
Increasing unusual put option volume: WGS WEN SCCO VNQ IP BBIO URNM BXP TTE SNAP FSLR NE
-
GeneDx Holdings (WGS) Misses Q1 EPS by 29c ; Offers Guidance
-
GeneDx to Acquire Fabric Genomics
-
TD Cowen: 'Top 10 Themes Coming Out of 45th Annual Health Care Conference'
-
GeneDx Holdings (WGS) 6900 contracts trade compared to 90-day average of 442 contracts as share price up 38%
-
GeneDx Holdings (WGS) Reports Q4 results; offers guidance
-
GeneDx Holdings (WGS) Announces ultraRapid Whole Genome Sequencing
-
GeneDx Integrates with Epic through launch on Aura
-
Craig-Hallum on GeneDx Holdings (WGS): 'Would Buy on Weakness' (Tuesday)
-
Jefferies Reiterates Hold Rating on GeneDx (WGS)
-
BTIG Defending GeneDx (WGS)
-
Grizzly Research is short GeneDx Holdings (WGS)
-
GeneDx (WGS) Announces Preliminary 2024 Financial Results
-
GeneDx (WGS) PT Raised to $118 at TD Cowen, Citing 'Strong Competitive Position'
-
GeneDx Holdings (WGS) Appoints Bryan Dechairo as COO
-
GeneDx Holdings (WGS) Misses Q3 EPS by 31c
-
GeneDx Holdings (WGS) December 85 calls active as share price up 44%

